No shortage of antiretroviral drugs in India: Health Ministry
- July 27, 2022
- Posted by: OptimizeIAS Team
- Category: DPN Topics
No Comments
No shortage of antiretroviral drugs in India: Health Ministry
Subject :Polity
Section: National body
Context:
- There is adequate stock for around 95% ‘People Living with HIV’, Health Ministry clarifies
- 1st & 2nd line antiretroviral drugs ARV regimens like Tablet TLD (Tenofovir+ Lamivudine+ Dolutegravir) and other ARV regimens.
- India is one of the very few countries that provides free anti-retroviral medicines for life-long treatment of more than 14.5 lakh PLHIV through 680 antiretroviral therapy (ART) centres under its National AIDS Control Programme (NACP), which is fully funded by the Government of India.
- Tablet Dolutegravir (DTG)-50mg is required for around 50,000 PLHIV who are either on Alternate-1st/2nd or 3rd-line regimens, or those with TB co-infection
- National strategic plan (2017-24) and Mission SAMPARK
- The Ministry of Health and Family Welfare has launched the plan with aim to eradicating HIV/AIDS by 2030. It is expected to pave a roadmap for achieving the target of 90:90:90.
Target of 90:90:90-
- By 2020, 90% of all people living with HIV will know their HIV status.
- By 2020, 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy.
- By 2020, 90% of all people receiving antiretroviral therapy will have viral suppression.
- Mission ‘SAMPARK’ aimed at tracing those who are HIV positive and are to be brought under antiretroviral therapy (ART) services
- The Global Fund for AIDS TB and Malaria (GFTAM)
- Recently, India has announced a contribution of $22 million to the Global Fund for AIDS, TB and Malaria (GFTAM) for the 6th replenishment cycle (2020-22). The Global Fund is a partnership designed to accelerate the end of AIDS, tuberculosis and malaria.
- As an international organization, the Global Fund mobilizes and invests more than $4 billion a year to support programs run by local experts in more than 100 countries.